BERKELEY, Calif.--(BUSINESS WIRE)--Profluent, the AI-first protein design company, today debuted the OpenCRISPRTM initiative, releasing the world’s first open-source, AI-generated gene editor. With this launch, Profluent demonstrates the first successful precision editing of the human genome with customizable gene editors designed from scratch with AI..

加州伯克利（商业新闻短讯）--人工智能第一家蛋白质设计公司Profluent今天推出了OpenCRISPRTM计划，发布了世界上第一个开源的人工智能生成的基因编辑器。通过这次发布，Profluent展示了人类基因组的首次成功精确编辑，可定制的基因编辑器是用人工智能从头设计的。。

OpenCRISPR-1 is an AI-created gene editor, consisting of a Cas9-like protein and guide RNA, fully developed using Profluent’s large language models (LLMs). Through the training process for OpenCRISPR, the company’s AI learned from massive scale sequence and biological context to generate millions of diverse CRISPR-like proteins that do not occur in nature, thereby exponentially expanding virtually all known CRISPR families..

OpenCRISPR-1是一种人工智能创建的基因编辑器，由Cas9样蛋白和指导RNA组成，完全使用Profluent的大型语言模型（LLM）开发。通过OpenCRISPR的培训过程，该公司的人工智能从大规模序列和生物学背景中学习，产生了数百万种自然界中不存在的CRISPR样蛋白，从而成倍扩大了几乎所有已知的CRISPR家族。。

In its commitment to democratizing the technology, Profluent has launched OpenCRISPR-1 as an initial open-source release, making the AI-designed gene editor freely available to license for ethical research and commercial uses.

Profluent致力于使该技术民主化，推出了OpenCRISPR-1作为最初的开源版本，使人工智能设计的基因编辑器可以免费获得伦理研究和商业用途的许可。

“Attempting to edit human DNA with an AI-designed biological system was a scientific moonshot,” said Ali Madani, Profluent co-founder and Chief Executive Officer. “Our success points to a future where AI precisely designs what is needed to create a range of bespoke cures for disease. To spur innovation and democratization in gene editing, with the goal of pulling this future forward, we are open-sourcing the products of this initiative.”.

Profluent联合创始人兼首席执行官阿里·马达尼（AliMadani）表示：“试图用人工智能设计的生物系统编辑人类DNA是一个科学登月计划。”。“我们的成功指向了一个未来，人工智能可以精确地设计出一系列定制的疾病治疗方法。为了刺激基因编辑的创新和民主化，以推动这一未来，我们正在开放这一举措的产品。”。

Profluent’s hope is that CRISPR medicines become available to more patients who may benefit, and for a broader range of disorders. The unique power of AI is that it enables researchers to reimagine and build gene editing systems from the ground up, which would be impossible with conventional protein engineering methods.

Profluent希望CRISPR药物能够为更多可能受益的患者以及更广泛的疾病提供。人工智能的独特功能在于，它使研究人员能够从头开始重新想象和构建基因编辑系统，这在传统的蛋白质工程方法中是不可能的。

By growing the universe of CRISPR families and releasing foundational molecules that can be further built upon, this application of AI paves the way to greater access and lower costs for gene editing therapies..

通过扩大CRISPR家族的范围并释放可以进一步构建的基础分子，人工智能的这种应用为基因编辑疗法的更大获取和更低成本铺平了道路。。

“It’s phenomenal that the first CRISPR-based treatments for genetic diseases such as sickle cell disease are already changing the lives of patients, but there remains an urgent need to accelerate the development of this technology for thousands of other currently incurable diseases,” said Hilary Eaton, Chief Business Officer at Profluent.

Profluent首席商务官希拉里·伊顿（HilaryEaton）表示：“令人惊讶的是，第一批基于CRISPR的镰状细胞病等遗传疾病治疗方法已经改变了患者的生活，但仍然迫切需要加速这项技术的发展，以治疗数千种其他目前无法治愈的疾病。”。

“Our intention with OpenCRISPR is to partner with cutting-edge research institutions and drug developers with a powerful and practical way to safely expedite the development of new CRISPR genetic therapies.”.

“我们与OpenCRISPR的意图是与尖端研究机构和药物开发人员合作，以一种强大而实用的方式安全地加速新CRISPR基因疗法的开发。”。

“Today’s announcement is a watershed moment and the beginning of what we hope will be an iterative process as we embark on this next generation of building genetic medicines,” said Peter Cameron, Vice President and Head of Gene Editing at Profluent. “We encourage the gene editing community to pressure test OpenCRISPR-1.

Profluent副总裁兼基因编辑主管彼得·卡梅隆（PeterCameron）表示：“今天的宣布是一个分水岭，也是我们开始下一代构建基因药物的迭代过程的开始。”。“我们鼓励基因编辑界对OpenCRISPR-1进行压力测试。

If there are particular features that could be improved for a specific application, we’d like to know and can collaborate to optimize those properties.”.

如果有特定应用程序可以改进的特定功能，我们希望了解并可以合作优化这些属性。“。

Profluent has published the science behind its OpenCRISPR initiative in a preprint publication. In adherence to ethical standards, the company's OpenCRISPR license will contain certain excluded uses, such as human germline editing. For more details on OpenCRISPR, visit https://www.profluent.bio.

Profluent在一份预印本出版物中发表了其OpenCRISPR倡议背后的科学。为了遵守道德标准，该公司的OpenCRISPR许可证将包含某些排除的用途，例如人类种系编辑。有关OpenCRISPR的更多详细信息，请访问https://www.profluent.bio.

About Profluent

关于Profluent

Profluent is an AI-first protein design company headquartered in Berkeley, CA. Founded in 2022, Profluent develops deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. The company is backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures.

Profluent是一家AI首家蛋白质设计公司，总部位于加利福尼亚州伯克利。成立于2022年，Profluent开发了深度生成模型，以设计和验证新颖的功能性蛋白质，从而彻底改变生物医学。该公司由领先的投资者支持，包括Spark Capital、Insight Partners、Air Street Capital、AIX Ventures和Convergent Ventures。

To learn more about Profluent’s mission to decode the language of life with AI, visit profluent.bio..

要了解更多关于Profluent用人工智能解码生活语言的使命，请访问Profluent.bio。。